Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)

Basit Öğe Kaydı
dc.authoridRimassa, Lorenza/0000-0001-9957-3615
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridSarker, Debashis/0000-0003-4814-8429
dc.authorwosidRimassa, Lorenza/N-4884-2016
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorMerle, P.
dc.contributor.authorRimassa, L.
dc.contributor.authorRyoo, B.
dc.contributor.authorCicin, I.
dc.contributor.authorHarris, W.
dc.contributor.authorBanu, E.
dc.contributor.authorSarker, D.
dc.date.accessioned2024-06-12T11:22:52Z
dc.date.available2024-06-12T11:22:52Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.descriptionESMO 20th World Congress on Gastrointestinal Cancer -- JUN 20-23, 2018 -- Barcelona, SPAINen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.identifier.endpage104en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpage104en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26090
dc.identifier.volume29en_US
dc.identifier.wosWOS:000439970900011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleAssessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu